Last reviewed · How we verify
LIOTHYRONINE SODIUM
At a glance
| Generic name | LIOTHYRONINE SODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1956 |
Approved indications
- Hypothyroidism
- Pituitary TSH Suppression
- Thyroid Suppression Test
Boxed warnings
- WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including liothyronine sodium tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning. Thyroid hormones, including liothyronine sodium tablets, should not be used for the treatment of obesity or for weight loss. Doses beyond the range of daily hormonal requirements may produce serious or even life-threatening manifestations of toxicity ( 6 , 7.7 , 10 ).
Common side effects
- Arrhythmias
- Myocardial infarction
- Dyspnea
- Headache
- Nervousness
- Irritability
- Insomnia
- Tremors
- Muscle weakness
- Increased appetite
- Weight loss
- Diarrhea
Serious adverse events
- Myocardial infarction
- Cardiac arrest
- Heart failure
- Angina
- Pseudotumor cerebri
- Slipped capital femoral epiphysis
- Craniosynostosis
- Premature closure of epiphyses
- Angioedema
- Serum sickness
Drug interactions
- Bile Acid Sequestrants (Colesevelam, Cholestyramine, Colestipol)
- Ion Exchange Resins (Kayexalate, Sevelamer)
- Clofibrate, Estrogen-containing oral contraceptives, Estrogens (oral), Heroin / Methadone, 5-Fluorouracil, Mitotane, Tamoxifen
- Androgens / Anabolic Steroids, Asparaginase, Glucocorticoids, Slow-Release Nicotinic Acid
- Salicylates (>2 g/day)
- Carbamazepine, Furosemide (>80 mg IV), Heparin, Hydantoins, Non-Steroidal Anti-inflammatory Drugs (Fenamates)
- Phenytoin
Key clinical trials
- Novel Approaches to the Treatment of Hypothyroidism (PHASE2, PHASE3)
- T4/T3 Therapy in Hypothyroidism (PHASE2)
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease (PHASE1, PHASE2)
- Optic Nerve Sheath Diameter and Postoperative Cognitive Disfunction at Laparoscopic Surgery
- A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LIOTHYRONINE SODIUM CI brief — competitive landscape report
- LIOTHYRONINE SODIUM updates RSS · CI watch RSS